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Introduction: Patients’ treatment satisfaction is important in deciding between available 
treatments for Type 2 diabetes (T2D). We present the results of the Diabetes Treatment 
Satisfaction Questionnaire (DTSQ) from a 44-week, parallel, open, randomized, 
multinational, multicentre clinical study comparing efficacy, safety and treatment satisfaction 
with OADs plus either insulin glargine (LANTUS®) once-daily or lispro at mealtimes (3x daily) 
in patients with T2D poorly controlled with OADs alone (APOLLO).  
Methods: The DTSQ was completed at screening, Week 20 and study endpoint (Week 44). 
The 8-items of the DTSQ are rated 0–6 and provide a treatment satisfaction score (maximum 
36=most satisfied). Two individual items measure perceived frequency of hyperglycaemia 
and hypoglycaemia (maximum frequency of hyper/hypoglycaemia=6). Differences between 
treatment groups were evaluated using ANCOVA with treatment group, language and current 
OAD intake as fixed factors and baseline values as covariates. 
Results: At baseline, treatment satisfaction scores were similar for the insulin glargine 
(25.98) and insulin lispro (26.38) groups (Table). Improvements in treatment satisfaction 
were seen at endpoint, and the improvement was greatest in the insulin glargine group. The 
change in score for perceived frequency of hyperglycaemia showed more improvement, and 
the score for perceived frequency of hypoglycaemia increased to a lesser extent for the 
glargine group. 
Discussion: This study demonstrates that once-daily insulin glargine was associated with 
greater improvements in treatment satisfaction compared with three-times-daily insulin lispro. 
 
 Insulin glargine 
(n=188) 
Insulin lispro 
(n=191) 
p 
 Mean±SD n Mean±SD n  
Efficacy   
HbA1c (%)   
Baseline 8.71±0.95 174 8.64±0.95 174 
Endpoint 6.96±0.67 174 6.77±0.83 174 n/s
   
DTSQ parameter   
Treatment satisfaction    
Baseline  25.98±7.99 187 26.38±7.87 188 
Endpoint  32.21±4.55 188 29.18±6.49 191 <0.0001
Perceived frequency of hyperglycaemia    
Baseline  3.85±1.90 186 4.03±1.86 185 
Endpoint  1.62±1.67 188 2.13±1.77 191 0.0034
Perceived frequency of hypoglycaemia   
Baseline  0.96±1.57 187 1.01±1.53 186 
Endpoint  1.23±1.37 188 1.95±1.64 191 <0.0001
n/s=not significant 
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